{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:00:22Z","timestamp":1773817222065,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1102604"],"award-info":[{"award-number":["APP1102604"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.soncn.2020.151047","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T01:53:01Z","timestamp":1595382781000},"page":"151047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Caitlin","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anis A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2020.151047_bib0001","unstructured":"Australian Institute of Health and Welfare. Cancer in Australia 2019. In: Cancer series no.119. Cat. no. CAN 123. Canberra: AIHW; 2019. Available at: https:\/\/www.aihw.gov.au\/getmedia\/8c9fcf52-0055-41a0-96d9-f81b0feb98cf\/aihw-can-123.pdf.aspx?inline=true."},{"key":"10.1016\/j.soncn.2020.151047_bib0002","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.soncn.2020.151047_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ajco.12761","article-title":"Cancer in Australia: actual incidence data from 1982 to 2013 and mortality data from 1982 to 2014 with projections to 2017","volume":"14","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.soncn.2020.151047_bib0004","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca Cancer J Clin"},{"key":"10.1016\/j.soncn.2020.151047_bib0005","unstructured":"Australian Institute of Health and Welfare. Burden of cancer in Australia: Australian burden of disease study 2011. In: Vol Australian Burden of Disease Study, series no. 12. Cat. no. BOD 13. Canberra: AIHW; 2017. Available at: https:\/\/www.aihw.gov.au\/getmedia\/a1aec7bd-ddb7-416f-9a7e-f2133cd5d4cb\/20965.pdf.aspx?inline=true."},{"key":"10.1016\/j.soncn.2020.151047_bib0006","first-page":"1","article-title":"Impact of financial costs of cancer on patients \u2013 the Australian experience","volume":"41","author":"Paul","year":"2017","journal-title":"Cancer Forum"},{"key":"10.1016\/j.soncn.2020.151047_bib0007","unstructured":"Australian Institute of Health and Welfare. Health system expenditure on cancer and other neoplasms in Australia, 2008\u201309. In: Vol Cancer series no. 81. Cat. no. 78. Canberra: AIHW; 2013. Available at: https:\/\/www.aihw.gov.au\/getmedia\/296395cc-f241-4c2f-a1a2-9e0b7c6a4d79\/16199.pdf.aspx?inline=true."},{"key":"10.1016\/j.soncn.2020.151047_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201552","article-title":"Health services costs for cancer care in Australia: estimates from the 45 and Up Study","volume":"13","author":"Goldsbury","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.soncn.2020.151047_bib0009","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/NCC.0000000000000482","article-title":"Unmet supportive care needs of men with locally advanced and metastatic prostate cancer on hormonal treatment: a mixed methods study","volume":"40","author":"Paterson","year":"2017","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.soncn.2020.151047_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019917","article-title":"Experiences of Australian men diagnosed with advanced prostate cancer: a qualitative study","volume":"8","author":"Chambers","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.soncn.2020.151047_bib0011","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1188\/17.ONF.E241-E249","article-title":"A Qualitative study exploring models of supportive care in men and their partners\/caregivers affected by metastatic prostate cancer","volume":"44","author":"Primeau","year":"2017","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.soncn.2020.151047_bib0012","unstructured":"Aranda S, Yates P. A national professional development framework for cancer nursing. 2nd ed. Canberra: The National Cancer Nursing Education Project (EdCaN), Cancer Australia; 2009. Available at: http:\/\/edcan.org.au\/assets\/edcan\/files\/docs\/EdCanWeb_2nded.pdf."},{"key":"10.1016\/j.soncn.2020.151047_bib0013","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejon.2018.10.007","article-title":"A pilot randomised controlled trial of a multimodal supportive care (ThriverCare) intervention for managing unmet supportive care needs in men with metastatic prostate cancer on hormonal treatment and their partner\/caregivers","volume":"37","author":"Paterson","year":"2018","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.soncn.2020.151047_bib0014","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0015","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.soncn.2020.151047_bib0016","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0017","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0018","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0019","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0020","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0021","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2020.151047_bib0022","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.soncn.2020.151047_bib0023","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisolone in metastatic castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0025","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2020.151047_bib0026","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2020.151047_bib0027","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.soncn.2020.151047_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2019.11.010","article-title":"Androgen deprivation therapy and mental health: impact on depression and cognition","author":"Izard","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.soncn.2020.151047_bib0029","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/pon.1427","article-title":"Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer","volume":"18","author":"Ulloa","year":"2009","journal-title":"Psychooncology"},{"key":"10.1016\/j.soncn.2020.151047_bib0030","first-page":"e12392","article-title":"Financial toxicity: a potential side effect of prostate cancer treatment among Australian men","volume":"26","author":"Gordon","year":"2017","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.soncn.2020.151047_bib0031","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejon.2017.04.004","article-title":"Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals","volume":"29","author":"Lamb","year":"2017","journal-title":"Eur J Oncol Nurs"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208120300620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208120300620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:35:49Z","timestamp":1760081749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208120300620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0749208120300620"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2020.151047","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2020.151047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151047"}}